This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Jun;18(6):322.

doi: 10.1038/s41571-021-00517-w.

Belzutifan has potential in RCC

Affiliations

PMID: 33931768
DOI: 10.1038/s41571-021-00517-w

Comment

Belzutifan has potential in RCC

Diana Romero. Nat Rev Clin Oncol. 2021 Jun.

. 2021 Jun;18(6):322.

doi: 10.1038/s41571-021-00517-w.

Author

Affiliation

¹ Nature Reviews Clinical Oncology, . nrclinonc@nature.com.

PMID: 33931768
DOI: 10.1038/s41571-021-00517-w

No abstract available

PubMed Disclaimer

Comment on

Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E. Choueiri TK, et al. Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22. Nat Med. 2021. PMID: 33888901 Free PMC article. Clinical Trial.

References

1. Nat Med. 2021 May;27(5):802-805 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information